Advanced search
Publication Cover
Hematology Volume 27, 2022 - Issue 1
Submit an article Journal homepage
5,062
Views
5
CrossRef citations to date
0
Altmetric
Rapid Communication

Outcomes of anti-CD38 isatuximab plus pomalidomide and dexamethasone in five relapsed myeloma patients with prior exposure to anti-C38 daratumumab: case series

Faouzi Djebbaria Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, UKCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-9578-7632
ORCID Icon,
Matt Poyntonb Royal Berkshire Hospital, Reading, UK
,
Gina Sanghac Milton Keynes Hospital, Milton Keynes, UK
,
Laura Andersond Royal United Hospital Bath, Bath, UK
,
Rebecca Maddamse Poole Hospital, Poole, UK
,
Toby A. Eyrea Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK
,
Grant Vallancea Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK
,
Supratik Basuf The Royal Wolverhampton NHS Trust, Wolverhampton, UK;g Faculty of Science and Engineering, University of Wolverhampton, Wolverhampton, UK;h West Midlands Research Consortium (WMRC), West Midlands, UK
&
Karthik Ramasamya Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK
 show all
Pages 204-207 | Published online: 08 Feb 2022

References

  • Van Bueren L, Jakobs D, Kaldenhoven N, et al. Direct in vitro comparison of daratumumab with surrogate analogs of CD38 antibodies MOR03087, SAR650984 and Ab79. Blood. 2014;124:3474. DOI:10.1182/blood.V124.21.3474.3474.
  • Jiang H, Acharya C, An G, et al. SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide. Leukemia. 2016;30:399–408.
  • Martin TG, Corzo K, Chiron M, et al. Therapeutic opportunities with pharmacological inhibition of CD38 with isatuximab. Cells. 2019;8:1522. DOI:10.3390/cells8121522.
  • Attal M, Richardson PG, Rajkumar SV, et al. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Lancet. 2019;394(10214):2096–2107.
  • National Institute for Health and Care Excellence. Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma. 2020; [last accessed 2021 June 22]. Available from: https://www.nice.org.uk/guidance/TA658.
  • Becnel MR, Horowitz SB, Thomas SK, et al. Descriptive analysis of isatuximab use following prior daratumumab in patients with relapsed/refractory multiple myeloma. Blood. 2020;136:20–21.
  • Mikhael J, Belhadj-Merzoug K, Hulin C, et al. A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab. Blood Cancer J. 2021;11:89. DOI:10.1038/s41408-021-00478-4.
  • Common Terminology Criteria for Adverse Events (CTCAE) v5. European Organisation for Research and Treatment of Cancer. 2017. [last accessed 2021 August 9]. Available at: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_5 ( 7.pdf.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.